Latest Sustainability News

Recce Pharmaceuticals has commenced patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, supported by promising antibacterial efficacy data and extended funding arrangements.

Burley Minerals advances its iron ore and lithium exploration with planned drilling at Cane Bore and Broad Flat Well, while navigating heritage survey delays and legal access issues.

Cyclone Metals advances its flagship Iron Bear Project despite a minor delay in drilling caused by First Nations election disputes, while strengthening its cash position through significant share sales.

Tolu Minerals has secured a $60.5 million capital raise and appointed Dr Chris Muller as CEO, setting the stage for a production restart at Tolukuma Gold Mine in the second half of 2026 alongside a major drilling program.

APC Minerals reported encouraging gold intersections from its Laverton Downs drilling program while navigating a tight cash position and ongoing asset acquisition efforts.

Complii FinTech Solutions reported a 4.9% year-on-year increase in annual recurring revenue, progressed a major CRM system upgrade, and secured a $1.217 million R&D rebate in Q1 FY26, while managing cash flow pressures.

Catalyst Metals has doubled its Plutonic Gold Belt reserves to 1.5 million ounces, setting the stage to double annual gold production to 200,000 ounces over the next decade. The company’s strategic mine developments and exploration programs underpin a confident growth trajectory.

Atlantic Lithium has finalized revised fiscal terms with the Ghanaian government for its Ewoyaa Lithium Project and awaits parliamentary ratification, while reporting strong exploration results in Côte d’Ivoire and securing significant funding agreements.

Admiralty Resources NL reported a mixed cash flow quarter ending September 2025, balancing operating outflows with investing and financing inflows to maintain a solid funding runway.

Admiralty Resources NL reported steady production growth at its Mariposa Iron Ore Project in Chile, securing key export approvals and infrastructure progress despite a delay in its audited financial statements that led to ASX suspension.

Adherium Limited reports a strong quarter with a 55% increase in device shipments and groundbreaking clinical results from its iCARE study, alongside securing over $2.6 million in post-quarter funding.

Chimeric Therapeutics has progressed its CHM CDH17 and CHM CORE-NK clinical trials with promising safety and efficacy signals, while securing a key manufacturing partnership and appointing a renowned haematologist to its board. However, the company faces a pressing cash runway challenge.